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The advent of cloning herpesviral genomes as bacterial artificial chromosomes (BACs) has made herpesviruses accessible to
bacterial genetics and has thus revolutionised their mutagenesis. This opened all possibilities of reverse genetics to ask scientific
questions by introducing precisely accurate mutations into the viral genome for testing their influence on the phenotype under
study or to create phenotypes of interest. Here, we report on our experience with using BAC technology for a designed modulation
of viral antigenicity and immunogenicity with focus on the CD8 T-cell response. One approach is replacing an intrinsic antigenic
peptide in a viral carrier protein with a foreign antigenic sequence, a strategy that we have termed “orthotopic peptide swap”.
Another approach is the functional deletion of an antigenic peptide by point mutation of its C-terminal MHC class-I anchor
residue. We discuss the concepts and summarize recently published major scientific results obtained with immunological mutants
of murine cytomegalovirus.
1. Introduction
Cytomegaloviruses (CMVs) are large enveloped DNA viruses
with a linear double-stranded genome of more than 200 kbp
in size and a correspondingly high coding capacity of
∼160–170 open reading frames (ORFs) [1–4]. Human CMV
(hCMV) is the prototype virus of the Betaherpesvirinae, a
subfamily of the Herpesviridae, and is one of the eight known
human pathogens of the herpesvirus family, namely, Human
Herpesvirus 5 (HHV-5), according to virus taxonomy. It
is ubiquitous in the human population with a prevalence
among adults of about 50%–70% in industrialised and up
to 100% in developing countries. Eﬃcient control by the
eﬀector mechanisms of both innate and adaptive immunity
prevents overt disease in immunocompetent individuals;
however, like with all herpesviruses, after resolution of
productive infection, the viral genome is maintained lifelong
in a nonproductive state of infection known as viral latency
(for reviews, see [5–7]). During latency, by definition [7],
infectious particles are no longer produced, and viral genes
of the productive cycle are mostly silenced. In more recent
concepts, CMV latency is regarded as a more dynamic
state of gene silencing and desilencing, with episodes of
reactivated viral gene expression that are sensed and ter-
minated by eﬀector-memory CD8 T cells before virions
can be assembled and released [8]. This “nonproductive”
antigenic activity during latency is considered to be the
driving force for repetitive T-cell restimulation and clonal
expansion, a phenomenon known as “memory inflation”
(for reviews, see [9, 10]). Accordingly, interrupting this
immune control of latency by immunosuppressive measures
allows reactivated viral gene expression to proceed to the
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production of infectious virions [11, 12] resulting in recur-
rent infection and organ disease. Generally, in individuals
with an immature or compromised immune system, acute
or recurrent hCMV infection can cause severe disease with
multiple organ manifestations such as interstitial pneumo-
nia, hepatitis, gastrointestinal diseases, and bone marrow
failure. The reactivation of latent hCMV is a frequent com-
plication after iatrogenic immunosuppression in allogeneic
solid organ transplantation or hematoablative conditioning
in hematopoietic stem cell transplantation (HSCT), resulting
in CMV organ disease and graft failure (reviewed in [13]). In
particular, the acute congenital, intrauterine hCMV infection
of an embryo or fetus is a major clinical problem. It can
result in miscarriage and stillbirth or cause multiple im-
mediate or delayed birth defects, including microenceph-
aly/microcephaly, intracranial calcifications, cerebral palsy,
epilepsy, vision loss, sensorineural hearing loss, develop-
mental delays, and mental retardation (for impressive case
reports, go to http://williamshaﬀer.org/cmv/). Development
of an hCMV vaccine has, therefore, been assigned a high pri-
ority by the Institute of Medicine, The National Academies,
Washington (see [14], reviewed in [15]). It is thus of utmost
importance to better understand the principles of immunity
against CMVs in acute and latent infection.
Since betaherpesviruses are strictly host species-specific
in their replication [16], hCMV infection and pathogenesis
cannot be analysed in animal models, except in humanized
mice with human tissue implants, which is highly demanding
and has limitations [17–20]. The immune response to hCMV
can be inferred from immunological monitoring in hCMV-
infected (seropositive) but otherwise healthy volunteers or
in patients with acute or reactivated hCMV infection (for a
review, see [21]). A problem is, however, that the genetics
and hence the proteomes and the repertoire of immunogenic
sequences of patients’ virus isolates are not known in advance
and mostly not even accessible retrospectively. An aimed
experimentation with defined virus strains—natural ones or
engineered viruses—prohibits, of course. Studying animal
CMVs paradigmatically in the corresponding natural host
is, therefore, used for identifying principles of predictive
value. Among animal models of CMV infection [22–24], of
which the rhesus macaque model is most likely closest to
the situation in humans [25, 26], the mouse model using
murine CMV (mCMV) is currently still most advanced
[9, 27, 28], mainly for logistic reasons and because of defined
and easily manipulable host genetics and the availability of
a wealth of already existing mouse mutants. The probably
most relevant contribution of the mouse model so far was
the identification of CD8 T cells as the principal antiviral
eﬀector cells operative in the cellular immunotherapy of
CMV disease in immunocompromised HSCT recipients (see
[29–34]; for a recent review, see [35]), a finding that was suc-
cessfully translated into clinical research, trials, and practice
[36–40].
CD8 T cells recognize infected cells through the inter-
action of their T cell receptor (TCR) with a cell-surface
presentation complex formed by an antigenic viral peptide
bound to a major histocompatibility complex class I (MHC-
I) molecule (see [41]; for a review see [42]). The following
presented viral peptides are generated by proteolytic pro-
cessing of viral proteins, usually in the proteasome, and
are transported via the TAP-complex into the lumen of the
endoplasmic reticulum, where they bind to nascent MHC-
I proteins under the assistance of chaperones. Finally, the
peptide-loaded MHC-I (pMHC) complexes travel with the
vesicular flow to the cell surface [43–45].
The first antigenic peptide of mCMV to be identified was
the IE1 peptide 168YPHFMPTNL176 (IE168−176) that is de-
rived from the regulatory IE1 protein pp76/89 (encoded by
ORFm123) and is presented by the murine MHC-I molecule
H-2-Ld [46, 47]. It was only during the past decade that
a number of further antigenic peptides of mCMV were
identified for MHC haplotypes H-2d (summarized in [35])
and H-2b [48]. It is self-evident that the repertoire of
potentially antigenic viral peptides in a certain virus-host
combination depends on the sequences of the viral proteins,
that is the proteome of the particular virus strain/isolate,
as well as on the presenting MHC-I alleles expressed in the
individual host. In addition, whether a presented peptide
is actually immunogenic also depends on the individual
TCR repertoire of the host, which is generated by random
gene rearrangements and diﬀers even between genetically
identical individuals such as in mouse inbred strains. So,
the repertoire of responding CD8 T cells is unique for
each individual virus-host pair. That nevertheless certain
antigenic peptides elicit a quantitatively higher response than
others, a phenomenon known as immunodominance, is not
yet fully understood (reviewed in [49]). Whilst overlapping
15-amino acid peptides representing all known ORFs for a
pangenomic evaluation of hCMV immunogenicity revealed
antigenic peptides for most ORFs with memory CD8 T cells
derived from the MHC-I polymorphic test population of
33 hCMV-seropositive volunteers enrolled to represent high
MHC allele coverage, individual persons responded only to
a limited number of ORFs, namely, between only 1 and
32 ORFs with a median value of 8 ORFs [50]. This is in good
accordance with the number of antigenic ORFs identified
with an mCMV library of ORF transfectants, with the CD8
T-cell response in C57BL/6 mice, haplotype H-2b [48] being
somewhat broader than in BALB/c mice, haplotype H-2d
[51, 52]. It is important to note that specificity repertoires
diﬀer between acute and memory CD8 T-cell responses [53,
54], since repeated restimulation of only certain specificities
by viral gene expression and presentation of antigenic viral
peptides/epitopes during latency (for a review, see [9]) is
supposed to shape and restrict immunological memory. CD8
T-cell repertoire focusing during selection into memory,
concomitant with clonal expansion and increasing oligo-
clonality, applies not only to diﬀerent epitopes but also
to TCR clonotypes specific for defined individual epitopes
[55].
Here, we review our experience and findings using
bacterial artificial chromosome (BAC) mutagenesis of the
mCMV genome to specifically alter the antigenic potential of
the virus, that is, its “immunome”, by deleting immunodom-
inant epitopes and by replacement of intrinsic antigenic
peptides with foreign antigenic peptides.
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2. Manipulation of the CMV Genome
2.1. Genetic Manipulation in the Pre-BAC Era. For a long
time, a major limitation in manipulating CMV-genomes
has been the cloning and the handling of these large DNA
molecules of ∼230 kbp in size. So, it was then not possible
to clone the complete genomes as single molecules. Instead,
a cosmid library was used to clone overlapping fragments
of the hCMV genome [56]. This allowed manipulating
parts of the viral genome, cloned into plasmids with
classical cloning methods, by introducing mutations like
deletions or insertions into viral genes. Plasmids carrying the
mutated sequences were subsequently cotransfected with the
conventionally isolated wild-type (WT) viral genomic DNA
to retrieve recombinant genomes by spontaneous homolo-
gous recombination [57]. Alternatively, transfection of the
complete set of overlapping cosmids was used to produce
recombinant viral genomes [58]. Other investigators have
used site-specific recombination in mammalian cells that
were cotransfected with viral genomes and PCR-fragments
containing a selectable marker flanked by sequences deter-
mining the target region in the viral genome [59]. However,
all these methods have drawbacks. (I) The procedure is
very time consuming due to the slow replication kinetics
of hCMV in cell culture. (II) After transfection, cells always
contain a mixture of viral WT and mutated genomes so that
cross-complementation can occur. (III) In order to select
successfully mutated viral genomes, viral particles need to
be plaque-purified in presence of a drug for selection during
at least three passages. (IV) The eﬃciency of homologous
recombination in eukaryotic cells is low compared to
bacterial systems. (V) The dependence of these techniques
on replicating virus during the selection process does not
allow the isolation of mutants defective in replication. The
cloning of CMV genomes into BACs allowed to overcome
these limitations.
2.2. Entrapping the Viral Genome. The development of BACs
from the E. coli F-factor allowed cloning of DNA fragments
of more than 100 kbp in size in contrast to conventional
plasmids and cosmids, which were limited to ∼20 kbp and
∼40 kbp, respectively [60]. This allowed Messerle and col-
leagues in their pioneering work [61] to clone the full-length
mCMV genome, as the first genome of a herpesvirus, into a
single molecule for propagation in bacteria. To achieve this,
the BAC-vector was integrated into a nonessential stretch
of the mCMV genome, replacing the region ranging from
ORFm151 to ORFm158. In comparison with WT virus, how-
ever, the virus reconstituted from this BAC prototype was
impaired in its replicative fitness in vivo due to the deletion
of viral immunomodulatory sequences and the integration
of BAC vector sequences [62]. For instance, deletion of
ORFm152 in the viral genome attenuates the virus by the loss
of the most potent dual immunoevasin of mCMV, protein
gp40/m152, which simultaneously inhibits the CD8 T-cell
response by retaining pMHC in a cis-Golgi compartment
and the NK cell response by downmodulating RAE-1 ligands
of the activatory NK cell receptor NKG2D [63–66]. In
order to reconstitute viral pathogenicity, the deleted genomic
region was reinserted and, in addition, the BAC vector
sequence was flanked by short identical sequences to allow
its elimination by homologous recombination during virus
passage in eukaryotic cells [62]. The resulting BAC is larger
in size than is the regular viral capsid packaging capacity.
Thus, viral genomes that have undergone recombination
are preferentially encapsidated during intranuclear capsid
assembly, which results in a rapid loss of bacterial sequences
from the recombinant BAC genomes during the propagation
of the reconstituted virus. The successful cloning of the
mCMV genome paved the way for the cloning of other
herpesvirus genomes, for example of hCMV [67], HSV-1
[68], EBV [69], and MHV-68 [70].
Most importantly, the cloning of the complete viral
genome as a BAC made it accessible to the powerful
mutagenesis methods available in the E. coli system and
thus allowed targeting any site in the viral genome for site-
directed mutation (see [71, 72], for a review see [73]). BAC
recombination systems have many advantages. (I) Use of
the E. coli recombination system allows an eﬀective and
rapid mutation and selection process compared to the fairly
ineﬃcient and slow recombination in eukaryotic cells. (II) It
enables the introduction of insertion-, deletion- and point-
mutations. (III) The low copy numbers of the BAC per
bacterial cell make it possible to isolate genetically defined
mutants with only minimal risk of WT contamination and
cross-complementation. (IV) Mutated genomes can easily
be characterised by restriction enzyme analysis, PCR, and
sequencing prior to virus reconstitution. (V) The process
of introducing the mutation is absolutely independent of
viral replication. Hence, it allows production and isolation
of mutants that lack essential functions. (VI) Mutations can
be easily reverted to demonstrate their causal involvement in
an observed phenotype.
Altogether, the cloning of CMV genomes as BACs opens
all possibilities to perform extensive studies of viral gene
functions by reverse genetics approaches including single
gene deletions and insertions, genome-wide analysis of loss-
of-function mutations, as well as a pinpointed analysis
of gene function by single amino acid replacement with
minimal alteration of the viral genome.
2.3. BAC Mutagenesis for the Introduction of Seamless Point
Mutations or Peptide Swaps. Up to date, several methods for
the mutagenesis of BACs are established, and they exhibit—
based on the type of mutation—specific advantages and
disadvantages. The fastest way for generating viral mutants,
for example, gene deletion mutants, is the use of linear
DNA fragments generated by PCR combined with the red
recombination enzymes of the bacteriophage λ [71, 74–77].
The major disadvantage of this method, however, is that a
selection marker or—after removing the selection marker
by Flp recombinase [78, 79]—some nucleotides remain in
the viral genome after mutagenesis. The removal of any
unwanted surplus nucleotides is indeed essential for the gen-
eration of viral mutants with changes in single nucleotides
or several codons for single amino acid or peptide sequence
replacements, for which maintenance of the respective viral
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ORF is mandatory. Three methods of choice exist to avoid
surplus nucleotides: (I) BAC recombination using the galK
selection marker [80], (II) markerless recombination using
the red recombinase system in combination with homing
endonuclease I-SceI cleavage [81], and (III) allelic exchange
using a shuttle plasmid [61, 62, 67, 82–84]. In contrast
to the single-step method using linear DNA fragments, all
three methods require two recombination steps, which is
somewhat more time consuming. Whilst the galK selection
and the cleavage by I-SceI involve special bacteria, the allelic
exchange requires the cloning of a shuttle plasmid. The
most common shuttle plasmid is the suicide vector pst76-
KSR [67, 85] that oﬀers a temperature-sensitive replication
and contains positive as well as negative selection markers.
Into this vector, the mutation, usually generated by PCR, is
integrated flanked by homologous regions of about 2 kbp
specific for the intended integration site in the CMV BAC
[61]. For constructing a functional shuttle vector several
cloning steps might be necessary, but once the plasmid is
cloned, it is widely applicable for introducing the respective
mutation into a range of BAC backbones that already carry
other mutations of interest (Figure 1).
3. Manipulation of Viral CD8 T-Cell Epitopes
Reverse genetics using BAC mutagenesis can be used to
engineer viruses with altered immunological properties, for
instance by physical or functional deletion of intrinsic anti-
genic peptides/epitopes or by insertion of foreign epitopes,
thereby modulating the viral “immunome” as a part of its
proteome. Deletion of intrinsic epitopes allows to evaluate
the contribution of the respective native sequences to the
antiviral immune response and to predict the consequences
of epitope loss as it might occur in natural virus variants
[88]. On the other hand, insertion of a foreign epitope in
a replicating vector virus can be used as a research tool
providing an “immunological tag” or as a vaccine approach
for improving the immune response against a pathogen
from which the “transgenic epitope” is derived. Table 1
compiles both types of mutant viruses and corresponding
revertant viruses produced in our lab and made available
upon request. Figures 2 and 4 illustrate these two concepts
of CMV immunomutagenesis.
3.1. Replacement of Single Amino Acid Residues in an
Antigenic Peptide. Single amino acid substitutions at either
the TCR contact sites or the MHC-I contact sites of an
antigenic peptide can be used to modulate or destroy the
antigenicity and immunogenicity of an epitope [10, 90–
92]. Such mutations can have a profound influence on
the CD8 T-cell response with an as minimal as possible
influence on protein function and viral biology, in particular
when substitutions are “conservative” avoiding replacement
of positively charged with negatively charged residues, of
charged with uncharged residues, of hydrophobic with
hydrophilic residues, or of conformation compatible with
conformation breaking residues and vice versa. In our lab,
we followed the established strategy of deleting one or
more epitopes functionally by loss-of-presentation point
mutagenesis replacing the respective C-terminal “anchor”
amino acid residue, which is usually a tailed hydrophobic
residue binding deeply into a hydrophobic pocket of the
peptide-presenting MHC-I molecule [93–97], with alanine
(A, Ala). This was achieved by BAC mutagenesis of the
mCMV genome, using the two-step replacement method
with shuttle vectors [8, 51] (Figure 1). The rationale of
this strategy is illustrated in Figure 2 for the example of
replacing the MHC-I H-2-Ld-binding C-terminal amino
acid leucine (L, Leu) in the immunodominant IE1 peptide
YPHFMPTNL (see the Introduction) with Ala, yielding the
mutation L176A in recombinant virus mCMV-IE1-L176A
[8] (Table 1). For this peptide, early studies [98] have
mapped TCR contact residues, MHC contact residues, and
neutral “spacer” residues by using the prototypic clonal
cytolytic T lymphocyte (CTL) line IE1, the clone with which
the IE1 peptide was originally identified [47], and a set
of synthetic peptides in which systematically each position
in the sequence was replaced with Ala, thereby identifying
proline (P, Pro) in position 2 and Leu in position 9 of the
peptide as the two residues that preferentially bind to the
presenting MHC-I molecule Ld. Since “spacer” residues can
potentially acquire an MHC binding function compensating
for an outage of a “budgetary” MHC binding residue [98],
loss of MHC-I binding by the point mutation must be
verified experimentally and for each peptide under study. In
the specific case of using clone IE1 as the probe, substitution
of Leu with Ala reduced the antigenicity of exogenously
peptide-loaded target cells by ∼ 6 log10 grades of molar
peptide concentration whereas the reduction was equivalent
with Val, less complete with Met, Ile, and Tyr, but more
complete with Asn and Trp [99]. We, nevertheless, chose the
replacement with Ala, since the small biochemical diﬀerence
of just an isopropyl group in the hydrophobic side chain
promised an only minimal impact, if any, on the regulatory
functions of the IE1 protein. This assumption was confirmed
experimentally in a number of functional assays, including
viral replicative fitness, IE1’s transcriptional transactivator
activity, and its capacity to dissociate repressive nuclear
domains ND10 [8]. It is important to note that the reduction
in the recognition of the mutated peptide is also influenced
by the functional avidity distribution of the CD8 T-cell
population used for the assay in that high-avidity eﬀector
cells can be triggered even by trace amounts of presented
peptide whereas low-avidity eﬀector cells may then fail. For
peptide SIINFEKA, we have indeed seen an only ∼10-fold
reduction of antigenicity compared with SIINFEKL when
high-avidity OT-I cells, carrying a transgenic Kb-SIINFEKL-
specific TCR [100], were stimulated with peptide-loaded
target cells (Gergely and Lemmermann, unpublished data).
Such a reduction may nevertheless be already critical for
the endogenous generation and presentation of pMHC
complexes, in particular when viral immunoevasins inhibit
their transport to the cell surface (see [89], reviewed in
[15, 52]). It is important to note that replacement of the
C-terminal residue of an antigenic peptide also impacts
its generation by proteasomal cleavage. This eﬀect of the
mutation can be predicted by in silico analysis with NetChop
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Figure 1: Method of herpesvirus point mutagenesis. (a) Site-directed mutagenesis by overlap extension. The dsDNA and primers are
represented by double lines and arrows, respectively. The direction of the arrows is indicating the 5′-to-3′ orientation of primers, which
are denoted by capital letters. The site of mutagenesis is marked with red symbol X. PCR amplificates yielded by PCR1 and PCR 2 served
as templates in the combination PCR (PCR3) performed with primers A and D to generate the final amplificate that includes the intended
point mutation. (b) Shuttle-plasmid allelic exchange in Escherichia coli. A shuttle plasmid harbouring the point mutation (red box) flanked
by homologous viral sequences (green and yellow boxes) is transformed into bacteria that contain the CMV BAC. The first homologous
recombination leads to formation of cointegrates due to recombination via one homology arm. Cointegrates are selected by chloramphenicol
(Cm) and kanamycin (Kn). Nonintegrated shuttle plasmids are removed at 43◦C. In the second recombination step, cointegrates are resolved
to generate either a WT viral BAC (via yellow box) or a mutant viral BAC (via green box). Clones still containing cointegrates are eliminated
by sucrose counterselection against SacB (gray box), and finally, bacterial clones containing either mutated or WT CMV BACs are isolated
(see [61, 62], for detailed description of the method, see [82]). (c) DNA of selected bacterial clones was tested for genomic structural
integrity, and the presence of the mutation was confirmed by sequencing. Reconstitution of BAC-derived recombinant virus was achieved
by transfection of mutated BAC DNA into permissive eukaryotic cells. After at least four viral passages and a second round of plaque
purification, PCRs were performed to verify the absence of BAC vector sequences [8].
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Figure 2: Loss-of-presentation mutagenesis of antigenic peptides. (Top) Genome size scale of mCMV and bidirectional gene pair
architecture of the major immediate-early (MIE) locus, with the promoter-enhancer-enhancer-promoter (PEEP) region flanked to the left
by the ie1/3 transcription unit (ORFs m123/M122) and to the right by gene ie2 (ORFm128) [86]. Exons are symbolized by boxes, with blue
boxes representing the four exons specifying the IE1 mRNA. The coding sequence for the antigenic IE1 peptide is located in exon 4. (Center)
Nucleotide and corresponding amino acid sequences for the authentic and mutated IE1 peptides, with mutations being highlighted in red.
(Bottom) Artwork models illustrating the binding of authentic and mutated IE1 peptides to the presenting MHC class-I molecule H-2-Ld
through the C-terminal anchor residue. The mutation is highlighted in red. L176A: mutant; A176L: authentic revertant; A176L∗: “wobble”
revertant maintaining a single nucleotide polymorphism as a genetic marker distinguishing it from WT and authentic revertant.
Table 1: Recombinant mCMVs with mutated CD8 T cell epitopes.
Virus mCMV-X Protein Replacement Resulting peptide Ref.
IE1-L176A IE1 L176A 168YPHFMPTNA176 [8]
IE1-A176L IE1 A176L[CTA] 168YPHFMPTNL176 [8]
IE1-A176L∗ IE1 A176L[CTT] 168YPHFMPTNL176 [8]
m164-I175A m164 I175A 167AGPPRYSRA175 [51]
m164-A175I m164 A175I 167AGPPRYSRI175 [51]
[IE1− L176A + m164− I175A] IE1+m164 L176A 168YPHFMPTNA176 [51]I175A 167AGPPRYSRA175
[IE1− A176L + m164− A175I] IE1+m164 A176L 168YPHFMPTNL176 [51]
A175I 167AGPPRYSRI175
SIINFEKL m164 167
AGPPRYSRI175
167SIINFEKL174 [89]→ 167SIINFEKL174
SIINFEKA m164 167
AGPPRYSRI175
167SIINFEKA174 [89]→ 167SIINFEKA174
Δm06m152-SIINFEKL m164 167
AGPPRYSRI175
167SIINFEKL174 [89]→ 167SIINFEKL174
Δm06m152-SIINFEKA m164 167
AGPPRYSRI175
167SIINFEKA174 [89]→ 167SIINFEKA174
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Figure 3: Verification of the loss-of-presentation phenotype. (a1) Loss of MHC-I H-2-Ld binding by replacement of the C-terminal anchor
residue Leu with Ala in the IE1 peptide. The response of a polyclonal IE1-specific CTLL, representing a broad TCR aﬃnity repertoire, was
measured in an IFN-γ-based ELISpot assay performed with Ld-expressing stimulator cells loaded exogenously with the indicated synthetic
peptides at graded molar concentrations. Recognition of pMHC complexes by CTL serves as an indirect measure for pMHC formation
by peptide binding to the presenting MHC-I molecule ∅, no peptide added. Note that presented IE1-Ala analog is recognized only by
high-avidity CTL after high-dose peptide loading. (a2) Loss of endogenous peptide presentation by the mutation L176A. The response of
an IE1-CTLL (see above) was measured with Ld-expressing stimulator cells that were infected with the indicated WT, mutant, or revertant
viruses (see also Table 1). n.i., not infected as a negative control. Note the selective lack of recognition of stimulator cells infected with mutant
virus mCMV-IE1-L176A. (b) Loss of in vivo immunogenicity by the mutation L176A. BALB/c (H-2d haplotype) mice were infected with
“wobble” revertant virus or with mutant virus (see Figure 2), and ex vivo isolated memory CD8 T cells were used as eﬀector cells in an IFN-
γ-based ELISpot assay performed with Ld-expressing stimulator cells that were loaded exogenously with saturating doses of the indicated
synthetic peptides ∅, no peptide added. Note the selective loss of IE1-specific CD8 T-cell priming after infection with mutant virus mCMV-
IE1-L176A. See Simon et al. [8] for further explanation and experimental details. Reproduced in modified arrangement from reference [8]
with permission by the Journal of Virology (American Society for Microbiology).
3.1 (http://www.cbs.dtu.dk/services/NetChop/) [101] as well
as with MAPPP (http://www.mpiib-berlin.mpg.de/MAPPP/
cleavage.html) [102] and experimentally determined by
in vitro proteasomal digestion of ∼25 amino acid-long
substrates (comprising the peptide of interest with its
authentic flanking residues), followed by mass spectrometric
identification and quantitation of processed fragments [103].
As a consequence, even if the reduction of MHC-I binding
of the mutated peptide is incomplete, a complete block of
endogenous pMHC formation and thus of peptide presen-
tation in infected cells can result from the combination of
ineﬃcient proteasomal cleavage and low aﬃnity of MHC-I
binding.
The ultimate functional consequences of the L176A
mutation in the IE1 peptide [8] are recapitulated in Figure 3.
Whilst exogenous loading of cell surface MHC-I Ld with the
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Figure 4: Principle of “orthotopic peptide swap” mutagenesis. (Top) Genome size scale of mCMV showing the genomic region of ORFs
m161-m166 enlarged. ORFs are symbolized by boxes, with the blue box representing ORFm164 encoding the viral carrier protein gp36.5 [87]
that includes the coding sequence for an intrinsic antigenic peptide that is immunodominant in the MHC haplotype H-2d [53]. Overlaps
with neighboring ORFs are indicated by blue-striped areas. (Center) Amino acid sequences of the intrinsic peptide to be replaced (blue
letters with large type size) and the replacing foreign peptide (red letters with large type size). Epitope-flanking residues in the host protein
sequence are shown in blue letters with small type size. (Bottom) Artwork models illustrating the binding of the intrinsic antigenic peptide
(blue chaplet) and of the inserted foreign antigenic peptide (red chaplet) to their respective presenting MHC-I molecules. Note that in the
documented case, peptide swap also leads to a change in MHC-restriction.
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Figure 5: Sketch of a criss-cross adoptive CD8 T-cell transfer experiment for evaluating the role of viral epitope mismatch in protection
against CMV disease by cellular immunotherapy. (a) Predicted result. (b) Actual result. Memory CD8 T-cell donors D-rev and D-mut
were immunocompetent BALB/c mice infected 6 months earlier with mCMV-rev and mCMV-mut, respectively, expressing or lacking two
immunodominant epitopes (IE1 and m164). Recipients R-rev and R-mut were immunocompromised BALB/c mice acutely infected with
the respective viruses shortly after the cell transfer. Arrows indicate the direction of cell transfer. The predicted and observed eﬃcacies of
antiviral protection are qualitatively classified from very eﬃcient (+++) to ineﬃcient (). Experimental assessment of antiviral protection was
performed by measuring virus replication in spleen, lungs, and liver. For experimental details and the original quantitative data, see [51].
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mutated peptide can be enforced by high peptide concentra-
tion (Figure 3(a1)), cells infected with virus mutant mCMV-
IE1-L176A are not recognized by polyclonal IE1 peptide-
specific CTL (Figure 3(a2)). Importantly, the mutated virus
also failed in priming of an IE1 epitope-specific CD8 T-cell
response in vivo (Figure 3(b)).
3.2. Insertion of Foreign Epitope-Encoding Sequences. Ectopic
expression of a full-length antigenic protein, for instance
ovalbumin (OVA) or the influenza virus nucleoprotein (Flu-
NP), is widely employed [104, 105] whereas more recent
approaches used an ectopic expression of a foreign antigenic
peptide C-terminally attached to an intrinsic viral protein
as a fusion protein. Specifically, Karrer and colleagues
[106] expressed the lymphocytic choriomeningitis virus-
(LCMV-) derived peptide GP(33−41) as well as the influenza
virus-derived peptide NP(366−374) in respective BAC-cloned
recombinant mCMVs in the context of the IE2 protein
under the control of the major immediate-early (MIE)
enhancer promoter and showed the induction of a protective
CD8 T-cell response against these unrelated viral pathogens.
This finding implies successful proteasomal processing of
the peptides from the respective fusion proteins. A similar
approach was used by Peter Doherty’s group in the influenza
virus system, namely, the insertion of the OVA-derived
peptide SIINFEKL (OVA(257−264)) into the neuraminidase
stalk [107]. In our lab, a modified approach was taken
recently, namely, an “orthotopic peptide swap” mutation
(Figure 4) replacing an immunodominant peptide in a
nonessential viral carrier protein, specifically peptide AGP-
PRYSRI in protein gp36.5/m164 [87], position precisely with
a foreign antigenic peptide, with SIINFEKL in the specific
case [89] (Table 1). The rationale for this strategy was to
choose a viral protein as a carrier protein that based on
its expression kinetics, abundance, and biochemical features
supports the processing of an immunodominant peptide,
as well as an integration site that is flanked by sequences
which support proteasomal cleavage in principle. Although
each modification of a viral protein, regardless of whether
sequences are replaced or additional sequences attached,
can alter its conformation and can have adverse or more
subtle and diﬃcult to predict eﬀects on viral functions,
which may apply even to proteins that are nonessential
for viral replication, orthotopic peptide swap represents the
minimal manipulation needed for the intended immuno-
logical phenotype. Nonetheless, we routinely measure viral
replicative fitness in vivo by virus doubling times in various
immunocompromised host organs to exclude replicative
attenuation of the mutant [8, 86, 108]. One might argue that
orthotopic peptide swap automatically implies a phenotype
of reduced antigenicity and immunogenicity due to the
replacement of an immunodominant intrinsic epitope. It is,
therefore, important to emphasize that the replaced antigenic
peptide and the replacing antigenic peptide are chosen so
as to diﬀer in their MHC-I restriction. Specifically, in the
example of SIINFEKL presented by MHC-I allele Kb in
mice of H-2b haplotype, for instance, in C57BL/6 mice, the
replaced peptide was presented by the MHC-I allele Dd and
was thus immunodominant only in mice of H-2d haplotype,
for instance in BALB/c mice [89] (Figure 4).
4. Major Scientific Insights Gained with
BAC-Cloned Viral Epitope Mutants
During the past few years, our lab has generated a panel of
mCMV recombinants with manipulated CD8 T- cell epitopes
(Table 1). These recombinants have helped elucidating some
aspects of the interplay between mCMV and the immune
system of its host. Here, we briefly summarize published
findings made in our lab or by our associates.
4.1. Epitope-Specificity of CD8 T Cell-Mediated Antiviral
Protection. Earlier work had shown that CD8-positive CTL
lines (CTLL) specific for pMHC complexes formed with
mCMV-encoded antigenic peptides protect against mCMV
multiple-organ infection and disease upon adoptive cell
transfer into immunocompromised recipients, a preclinical
model for cytoimmunotherapy of CMV disease in the
immunocompromised host that is aimed at curing HSCT
recipients (reviewed in [35]). Notably, in the murine model,
CTLL of diﬀerent peptide specificities were similarly eﬃcient
in antiviral protection independent of the magnitude of
the CD8 T-cell response against the cognate pMHC during
mCMV infection, that is, independent of their so-called
“immunodominance”. In fact, even epitopes at the low end
of the response hierarchy with barely detectable in vivo
immunogenicity upon host infection, such as m04-Dd or
M84-Kd, mediated protection by the cognate CTLL [109,
110]. Although it has always been the tacit and generally
accepted understanding that antiviral protection by CTLL
is mediated by epitope-specific pMHC-TCR interaction,
this was never formally documented for protection against
CMV infection, and thus the virtual irrelevance of the type
of viral peptide for protection by CTLL in the adoptive
transfer experiments raised the question of whether receptor-
ligand pairs other than pMHC-TCR, for instance, RAE1-
NKG2D or yet unidentified interactions, might actually
trigger an antiviral eﬀector function of the CD8 T cells
and CTLL. Most relevant in this context are our observa-
tion that CTLL can indeed lyse B7-expressing target cells
through interaction with CD28 independent of pMHC-
TCR interaction (Holtappels and Reddehase, unpublished
data) and the published finding that CD28-B7 is critical
for early control of mCMV infection [111]. This issue was
finally settled by showing that IE1 epitope-specific CTLL
as well as memory CD8 T cells sort purified ex vivo with
pMHC multimers failed to protect adoptive cell transfer
recipients against infection with the loss-of-presentation
mutant mCMV-IE1-L176A but protected against infection
with the revertant virus mCMV-IE1-A176L [29]. Notably, in
this study, focal infiltration of infected host tissues by the
transferred IE1 epitope-specific cells required the presenta-
tion of the cognate epitope, indicating that virally induced
or encoded chemokines alone [112] may attract CD8 T cells
but are not suﬃcient to retain them at the sites of viral
replication.
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4.2. Impact of Antigenic Mismatches between Donor and
Recipient Virus Variants in Cytoimmunotherapy. Reactivated
CMV infection is the most critical viral complication
after HSCT. The risk of HSCT-associated CMV-disease
is defined by the CMV status of transplantation donor
(D) and recipient (R). Of the four possible combinations
(D−R−,D+R−,D−R+, and D+R+), D−R+ bears the highest risk
by reactivating latent CMV from the recipients’ own tissues
[21, 113]. In contrast, a protective eﬀect of preexisting donor
immunity leads to a lower risk of CMV disease in the D+R+
combination despite a potential additional virus reactivation
from the transplanted donor cells. One promising approach
for preventing CMV reactivation and disease is the adoptive
transfer, clinically also known as donor lymphocyte infusion
(DLI), of donor-derived CMV-specific CD8 T cells. Since
the donor’s CMV variant (CMV-D) and the recipient’s
CMV variant (CMV-R) can diﬀer in their antigenic peptide
repertoire, transferred donor immunity and recipient pMHC
presentation may, however, not always fully match, with
the consequence of an ineﬃcient antiviral control in the
recipients. We addressed this problem experimentally in the
BALB/c mouse model by using the dual epitope-loss-mutant
mCMV-[IE1 L176A + m164 I175A] (briefly mCMV-mut)
and the corresponding revertant virus mCMV-[IE1 A176L
+ m164 A175I] (briefly mCMV-rev) (Table 1) for infecting
immunocompetent donor mice and immunocompromised
recipient mice in all four possible combinations of antigenic
match and mismatch for a criss-cross adoptive transfer
experiment [51] (Figure 5). The IE1-Ld and m164-Dd pMHC
complexes have previously been identified as “immunodom-
inant” epitopes in the memory CD8 T-cell repertoire of
mCMV-infected BALB/c mice, as defined by the magnitude
of the immune response [53]. Thus, if donors are primed
with mCMV-mut, CD8 T cells of these two specificities
are missing in the memory CD8 T-cell pool for protection
against mCMV-rev infection of the recipients. Reciprocally,
if donors are primed with mCMV-rev, CD8 T cells of these
two specificities are useless for protection against mCMV-
mut infection of the recipients. In the first combination
(D-mut/R-rev), absence of “immunodominating” epitopes
was predicted to favor the expansion of donor CD8 T cells
specific for subdominant epitopes, and this compensation
may in part restore protective activity. In contrast, in
the second combination (D-rev/R-mut), the focus of the
donor immune response on the immunodominant epitopes
might inhibit the response to subdominant epitopes, a
mechanism known as “immunodomination”. Thus, from
the recipients’ perspective, the latter combination ought
to be most unfavorable for protection since the donor
immune response is directed against “useless epitopes” and
even disfavors “useful epitopes”. We, therefore, expected
a protection hierarchy of D-rev/R-rev > D-mut/R-mut >
D-mut/R-rev  D-rev/R-mut (Figure 5(a)). The result of
this experiment, however, did not really follow the theory
(Figure 5(b)). Protection of the recipients turned out to be
comparably eﬃcient in all four combinations, with some
disadvantage for D-mut/R-rev, suggesting that inhibition of
subdominant epitopes by dominant epitopes rather operates
on the level of antigen presentation by the infected target
cells in the recipients’ tissues. Altogether, these data are
encouraging from a medical point of view as they show
that CD8 T-cell-based immunotherapy of CMV infection is
rather robust, tolerating even major antigenicity diﬀerences
between CMV variants. The data also indicate that antiviral
protection does not critically depend on immunodominant
epitopes, which applies at least to complex viruses with high
coding capacity, as it is the case for CMVs.
4.3. Control of Cytomegalovirus Latency by Immune Sensing
of Transcriptional Reactivation Episodes. During mCMV
latency in the lungs, viral genomes are not silenced all
the time but spontaneous or cytokine-triggered desilencing
of genes can lead to transcriptional reactivation episodes
that are terminated before viral DNA replication and virion
assembly (reviewed in [9]). Theoretically, gene desilencing
might occur sporadically at any viral gene locus during
latency, but only desilencing at the MIE locus has the
potential to proceed in the viral replicative cycle, since IE
genes, specifically IE2 of hCMV and IE3 of mCMV, code for
essential transcriptional transactivators. Detection of mCMV
IE1 and IE2 transcripts in latently infected lungs, indicating
MIE locus desilencing [11, 114], along with the finding
that recently sensitized CD62L-low eﬀector-memory CD8
T cells specific for the IE1 peptide persist in the lungs
and increase in number during latency [115], led to the
hypothesis that episodes of transcriptional activity corre-
spond to episodes of antigenic activity driving the expansion
of the IE1 epitope-specific cells, which in turn terminate
the reactivation episodes by means of their antiviral eﬀector
functions. This is, in essence, what the “immune sensing
hypothesis of cytomegalovirus reactivation” proposes (see
[46, 115], reviewed in [9, 10]). For a limited number of
other mCMV epitopes, CD8 T cells also expand or “inflate”
during latency [53, 54], and this is usually regarded as an
indirect evidence for an expression of the corresponding viral
genes during latency. It must be noted, however, that the
prototype example IE1 still remains the only example for
which the transcripts were actually detected during latency.
A gap in the chain of evidence is the missing molecular
detection of the IE1 protein and of the presented IE1 peptide,
which may relate to the low incidence of transcriptional
episodes. We thus argued that genetic deletion of the IE1
epitope from the viral epitope repertoire, which precludes
immunological sensing of IE1 transcription episodes, should
alter the transcription profile in latently infected host
tissue. By using the loss-of-presentation mutant mCMV-
IE1-L176A in comparison to corresponding revertant viruses
(Figure 2), Simon and colleagues [8] could indeed document
an increased number of detectable IE1 transcription episodes
and a progression to splicing of the essential transactivator
transcript IE3. Thus, the epitope mutant provided the first
and still only molecular evidence for antigenic peptide
presentation during episodes of transcriptional reactivation.
4.4. Molecular Quantitation of mCMV-Immunoevasion.
CMVs code for glycoproteins that are dedicated to subvert
immune recognition of infected cells and are, therefore,
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referred to as “immunoevasins”, as “viral proteins interfering
with antigen presentation (VIPRs)”, or as “viral regulators
of antigen presentation (vRAPs)” [15, 52, 116, 117]. For
immunoevasins aﬀecting the MHC-I pathway of antigen
presentation, downmodulation of cell surface MHC-I is
a hallmark often used in cytofluorometric analyses as
an indicator of immunoevasin function. Since all MHC-I
molecules normally reach the cell surface via the constitutive
vesicular transport as pMHC complexes loaded with self-
peptides in uninfected cells or with self and viral peptides
in infected cells, downmodulation of cell surface MHC-I
impacts the presentation of antigenic peptides. The term
“downmodulation”, however, is somewhat imprecise with
regard to the underlying mechanism in that it leaves open
if MHC-I molecules are actively removed from the cell
surface or if their disappearance is indirectly mediated by the
immunoevasins and rather reflects constitutive cell surface
MHC-I turnover in the absence of resupply by newly gen-
erated pMHC complexes. Addressing this question requires
to distinguish between MHC-I present at the cell surface in
advance of infection and new pMHC complexes travelling to
the surface after viral peptide loading onto nascent MHC-
I molecules in the ER. For this, an antibody is needed that
specifically recognizes a defined pMHC complex, but to
date no such antibody is available for a complex between
an MHC-I molecule and a CMV peptide. To overcome
this technical limitation and to quantitate specific pMHC
complexes at the cell surface, we used BAC mutagenesis of
mCMV for “orthotopic peptide swap” replacing the intrinsic
antigenic sequence in the viral carrier protein gp36.5/m164
with the OVA-derived model peptide SIINFEKL [89] (Fig-
ure 4), for which a monoclonal antibody T-AG25.D1-
16 exists that recognizes the SIINFEKL-Kb presentation
complex [118]. With this tool (see Table 1 for the respective
viruses), we could show that after infection of cells in the
absence of viral immunoevasins ∼10% of all cell surface
Kb molecules present endogenously processed SIINFEKL
at the cell surface, namely ∼10,000 out of ∼100,000 in
absolute terms, which is an enormous occupancy by a single
antigenic peptide. Importantly, this number was reduced
to <100 SIINFEKL-Kb complexes after infection with the
corresponding virus expressing the immunoevasins. Thus,
immunoevasins strongly inhibit the transport of recently
formed pMHC complexes to the cell surface. To answer
the initial question of the mode of MHC-I cell surface
downmodulation, cell surface Kb molecules were exoge-
nously preloaded with synthetic SIINFEKL peptide followed
by infection with SIINFEKA viruses that were lacking or
expressing immunoevasins (see Table 1 for the respective
viruses) but were unable to present endogenously processed
SIINFEKL due to the C-terminal anchor residue mutation
(same principle as outlined in Figure 2). Notably, after a time
of infection when presentation of endogenously processed
peptide was already almost completely blocked, specifically
at 8 h, cell surface exposure of preloaded SIINFEKL-Kb
complexes was still hardly aﬀected. This data led us to
the conclusion that immunoevasins inhibit the transport of
endogenously loaded pMHC complexes to the cell surface
and that the eventual downmodulation of total MHC-I
cell surface expression results from turnover in the absence
of resupply. Block of pMHC resupply is explained by
retention of pMHC complexes in a cis-Golgi compartment
by mCMV immunoevasin gp40/m152 [66] and rerouting
of pMHC complexes for lysosomal degradation by mCMV
immunoevasin gp48/m06 [119].
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